| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
75,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
| Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
| Total People Sold |
3 |
4 |
7 |
10 |
| Total Sell Transactions |
3 |
6 |
11 |
22 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2018-03-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,437,000) |
59,464 |
|
- |
|
| Robin Sherrington |
EVP Bus. & Corp. Development |
• – – |
2018-03-15 |
4 |
D |
$4.63 |
$8,917 |
D/D |
(1,928) |
5,892 |
|
- |
|
| Robin Sherrington |
EVP Bus. & Corp. Development |
• – – |
2018-03-15 |
4 |
OE |
$3.77 |
$11,634 |
D/D |
3,086 |
7,820 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2018-03-14 |
4 |
OE |
$3.77 |
$11,634 |
D/D |
3,086 |
118,955 |
|
- |
|
| Pimstone Simon N. |
CEO |
• • – |
2018-03-12 |
4 |
OE |
$3.77 |
$38,786 |
D/D |
10,288 |
228,135 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2018-02-22 |
4 |
GA |
$0.00 |
$0 |
I/I |
21,180 |
97,066 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2018-02-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
29,580 |
131,607 |
|
- |
|
| Cohen Charles J. |
VP, Biology |
• – – |
2018-02-12 |
4 |
D |
$3.50 |
$79,342 |
D/D |
(22,669) |
4,079 |
|
- |
|
| Cohen Charles J. |
VP, Biology |
• – – |
2018-02-12 |
4 |
OE |
$3.71 |
$99,235 |
D/D |
26,748 |
26,748 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2017-11-15 |
4 |
B |
$2.22 |
$33,281 |
D/D |
15,000 |
44,210 |
2.39 |
- |
|
| Azab Mohammad |
Director |
– • – |
2017-09-22 |
4 |
B |
$2.95 |
$23,600 |
D/D |
8,000 |
29,210 |
2.39 |
- |
|
| Azab Mohammad |
Director |
– • – |
2017-09-21 |
4 |
B |
$2.95 |
$5,900 |
D/D |
2,000 |
21,210 |
2.39 |
- |
|
| Winquist Raymond |
Head, Translational Research |
• – – |
2017-08-18 |
4 |
B |
$3.00 |
$2,995 |
D/D |
1,000 |
1,000 |
2.66 |
- |
|
| Azab Mohammad |
Director |
– • – |
2017-08-18 |
4 |
B |
$2.90 |
$18,302 |
D/D |
6,312 |
19,210 |
2.39 |
- |
|
| Azab Mohammad |
Director |
– • – |
2017-08-17 |
4 |
B |
$2.65 |
$61 |
D/D |
23 |
12,898 |
2.31 |
- |
|
| Empfield James R. |
SVP, Drug Discovery |
• – – |
2017-08-15 |
4 |
B |
$2.48 |
$24,824 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-08-15 |
4 |
B |
$2.41 |
$45,489 |
D/D |
18,858 |
1,077,694 |
2.37 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-08-14 |
4 |
B |
$2.70 |
$111,778 |
D/D |
41,344 |
1,070,265 |
2.45 |
- |
|
| Graham Dawn |
Director |
– • – |
2017-08-14 |
4 |
B |
$2.82 |
$140,770 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| Hayden Michael R |
Director |
– • – |
2017-08-14 |
4 |
B |
$2.75 |
$41,247 |
D/D |
15,000 |
161,187 |
2.39 |
- |
|
| Gannon Steven |
Director |
– • – |
2017-08-11 |
4 |
B |
$2.82 |
$42,267 |
D/D |
15,000 |
15,000 |
2.39 |
- |
|
| Pimstone Simon N. |
President & CEO |
• • – |
2017-08-10 |
4 |
B |
$2.90 |
$17,400 |
D/D |
6,000 |
217,847 |
2.81 |
- |
|
| Patou Gary |
Director |
– • – |
2017-08-10 |
4 |
B |
$2.78 |
$20,836 |
I/I |
7,500 |
12,500 |
2.1 |
- |
|
| Scheller Richard H |
Director |
– • – |
2017-08-10 |
4 |
B |
$2.85 |
$19,950 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| Mortimer Ian |
CFO & COO |
• – – |
2017-08-10 |
4 |
B |
$2.90 |
$29,000 |
I/I |
10,000 |
14,300 |
1.99 |
- |
|
231 Records found
|
|
Page 6 of 10 |
|
|
